Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 4/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 2/20 | 0.43 |
| ▸ | HPGD | P15428 | 2/20 | 0.43 |
| ▸ | ACP3 | P15309 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.41 |
| ▸ | DRD2 | P14416 | 1/20 | 0.41 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.41 |
| ▸ | CNR1 | P21554 | 1/20 | 0.41 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.41 |
| ▸ | HTR2A | P28223 | 1/20 | 0.41 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.41 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.41 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.41 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10347376 | 0.81 | CYP2C19 (0.46) | CYP2C19CYP1A2CYP2C9CYP2D6TDP1 | |
| SCHEMBL6001657 | 0.81 | CYP1A2 (0.46) | CYP2C19CYP1A2CYP2C9CYP2D6TDP1 | |
| SCHEMBL9819905 | 0.81 | CYP1A2 (0.46) | CYP2C19CYP1A2CYP2C9CYP2D6TDP1 | |
| SCHEMBL10499434 | 0.80 | CYP1A2 (0.48) | CYP2C19CYP1A2CYP2C9CYP2D6TDP1 | |
| SCHEMBL6694933 | 0.80 | CYP1A2 (0.48) | CYP2C19CYP1A2CYP2C9CYP2D6TDP1 | |
| SCHEMBL301409 | 0.80 | CYP2C19 (0.48) | CYP2C19CYP1A2CYP2C9CYP2D6TDP1 | |
| SCHEMBL2136855 | 0.80 | CYP2C19 (0.50) | CYP2C19CYP1A2CYP2C9CYP2D6TDP1 | |
| SCHEMBL1611481 | 0.80 | CYP2C19 (0.50) | CYP2C19CYP1A2CYP2C9CYP2D6TDP1 | |
| SCHEMBL7924285 | 0.80 | CYP2C19 (0.48) | CYP2C19CYP1A2CYP2C9CYP2D6TDP1 | |
| SCHEMBL1325661 | 0.80 | TDP1 (0.48) | CYP2C19CYP1A2CYP2C9CYP2D6TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0319986-B1 | Anti-plasmin depressant | NIPPON SHINYAKU CO LTD (JP) | 1997-03-12 | — | — | EP | claimed |
| US-7557127-B2 | HDAC inhibitor | ASTELLAS PHARMA INC. (JP) | 2009-07-07 | — | — | US | disclosed |
| CN-100497345-C | 2, 3-dihydro-6-nitroimidazolo [2,1-b] oxazole compounds for the treatment of tuberculosis | OTSUKA PHARMA CO LTD (JP) | 2009-06-10 | — | — | CN | disclosed |
| US-20090054464-A1 | HDAC INHIBITOR | ASTELLAS PHARMA INC. (JP) | 2009-02-26 | — | — | US | disclosed |
| US-7465731-B2 | HDAC inhibitor | ASTELLAS PHARMA INC. (JP) | 2008-12-16 | — | — | US | disclosed |
| EP-1776357-A1 | HYDROXYAMIDE COMPOUNDS HAVING ACTIVITY AS INHIBITORS OF HISTONE DEACETYLASE (HDAC) | Astellas Pharma Inc. (JP) | 2007-04-25 | — | — | EP | disclosed |
| CN-1878777-A | 2,3-dihydro-6-nitroimidazo (2,1-b) oxazole compounds for the treatment of tuberculosis | OTSUKA PHARMA CO LTD (JP) | 2006-12-13 | — | — | CN | disclosed |
| EP-1678185-A1 | 2,3-DIHYDRO-6-NITROIMIDAZO [2,1-B] OXAZOLE COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2006-07-12 | — | — | EP | disclosed |
| US-20060052599-A1 | HDAC inhibitor | ASTELLAS PHARMA INC. (JP) | 2006-03-09 | — | — | US | disclosed |
| WO-2006016680-A1 | HYDROXYAMIDE COMPOUNDS HAVING ACTIVITY AS INHIBITORS OF HISTONE DEACETYLASE (HDAC) | ASTELLAS PHARMA INC. (JP) | 2006-02-16 | — | — | WO | disclosed |
| WO-2005042542-A1 | 2,3-DIHYDRO-6-NITROIMIDAZO (2,1-B) OXAZOLE COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2005-05-12 | — | — | WO | disclosed |
| US-5968985-A | INHIBITORS OF SODIUM ION/HYDROGEN ION EXCHANGE IN CELLS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1999-10-19 | — | — | US | disclosed |
| EP-0319986-B1 | Anti-plasmin depressant | NIPPON SHINYAKU CO LTD (JP) | 1997-03-12 | — | — | EP | disclosed |
| EP-0733364-A1 | MEDICINAL COMPOSITION FOR CIRCULATORY ORGAN | NIPPON SHINYAKU COMPANY, LIMITED (JP) | 1996-09-25 | — | — | EP | disclosed |
| EP-0602242-A1 | BENZISOXAZOLE COMPOUND AND USE THEREOF | YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 1994-06-22 | — | — | EP | disclosed |
| US-5292750-A | piperidine compounds | NIPPON SHINYAKU CO. LTD. (JP) | 1994-03-08 | — | — | US | disclosed |
| US-5192772-A | Administering moranoline derivatives; anticoagulants | NIPPON SHINYAKU CO. LTD. (JP) | 1993-03-09 | — | — | US | disclosed |
| EP-0498680-A1 | New beta-amino-alpha-hydroxycarboxylic acids and their use | Sankyo Company Limited (JP) | 1992-08-12 | — | — | EP | disclosed |
| EP-0319986-A2 | Fibrinolytic agents | NIPPON SHINYAKU COMPANY, LIMITED (JP) | 1989-06-14 | — | — | EP | disclosed |
| EP-0099534-A1 | Cyclohexane-1,3-dione derivatives, process for their production and herbicides containing such compounds | BASF Aktiengesellschaft (DE) | 1984-02-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060052599-A1 | HDAC inhibitor | HDAC1, HDAC2, HDAC11 | CYP2C19 1505/4885CYP1A2 1586/4885CYP2C9 2265/4885 |
| US-20090054464-A1 | HDAC INHIBITOR | HDAC1, HDAC2, HDAC8 | CYP2C19 1053/4885CYP1A2 1012/4885CYP2C9 2042/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.